Targeting microRNA-485-3p blocks alzheimer’s disease progression

Han Seok Koh, Sangjoon Lee, Hyo Jin Lee, Jae-Woong Min, Takeshi Iwatsubo, Charlotte E. Teunissen, Hyun-Jeong Cho*, Jin-Hyeob Ryu*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Alzheimer’s disease (AD) is a form of dementia characterized by progressive memory decline and cognitive dysfunction. With only one FDA-approved therapy, effective treatment strategies for AD are urgently needed. In this study, we found that microRNA-485-3p (miR-485-3p) was overexpressed in the brain tissues, cerebrospinal fluid, and plasma of patients with AD, and its antisense oligonucleotide (ASO) reduced Aβ plaque accumulation, tau pathology development, neuroinflammation, and cognitive decline in a transgenic mouse model of AD. Mechanistically, miR-485-3p ASO enhanced Aβ clearance via CD36-mediated phagocytosis of Aβ in vitro and in vivo. Furthermore, miR-485-3p ASO administration reduced apoptosis, thereby effectively decreasing truncated tau levels. Moreover, miR-485-3p ASO treatment reduced secretion of proinflammatory cytokines, including IL-1β and TNF-α, and eventually relieved cognitive impairment. Collectively, our findings suggest that miR-485-3p is a useful biomarker of the inflammatory pathophysiology of AD and that miR-485-3p ASO represents a potential therapeutic candidate for managing AD pathology and cognitive decline.
Original languageEnglish
Article number13136
JournalInternational Journal of Molecular Sciences
Issue number23
Publication statusPublished - 1 Dec 2021

Cite this